Efficacy and cardiotoxicity of liposomal doxorubicin (Myocet) as a part of neoadjuvant therapy with paclitaxel and trastuzumab in HER2-positive operable breast cancer
Latest Information Update: 20 Jan 2020
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Paclitaxel; Trastuzumab
- Indications Early breast cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 14 Dec 2019 Results (N=60), diagnosed from August 2016 to May 2019 assessing the efficacy and cardiotoxicity in patients with HER2-positive operable breast cancer treated in neoadjuvant setting with trastuzumab and pertuzumab, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 07 Feb 2019 New trial record